Checkpoint Therapeutics (CKPT) Expected to Announce Quarterly Earnings on Friday

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Friday, May 9th. Analysts expect Checkpoint Therapeutics to post earnings of ($0.10) per share for the quarter.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.47). The firm had revenue of $0.04 million during the quarter.

Checkpoint Therapeutics Price Performance

Shares of Checkpoint Therapeutics stock remained flat at $4.15 during midday trading on Wednesday. The stock had a trading volume of 929,902 shares, compared to its average volume of 1,256,635. The company's fifty day simple moving average is $3.89 and its 200-day simple moving average is $3.59. The stock has a market cap of $347.62 million, a price-to-earnings ratio of -2.26 and a beta of 1.18. Checkpoint Therapeutics has a 1-year low of $1.47 and a 1-year high of $4.50.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a "neutral" rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. Lake Street Capital restated a "hold" rating and issued a $4.10 price objective (down from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. Finally, D. Boral Capital reissued a "buy" rating and set a $4.80 price objective on shares of Checkpoint Therapeutics in a research note on Monday, March 31st.

Insider Activity at Checkpoint Therapeutics

In other news, CEO James F. Oliviero III sold 9,233 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $3.41, for a total value of $31,484.53. Following the completion of the transaction, the chief executive officer now directly owns 3,785,350 shares in the company, valued at approximately $12,908,043.50. This represents a 0.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO William Garrett Gray sold 12,322 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total transaction of $49,904.10. Following the completion of the transaction, the chief financial officer now owns 1,446,322 shares of the company's stock, valued at approximately $5,857,604.10. This trade represents a 0.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 121,086 shares of company stock worth $446,879. Company insiders own 2.10% of the company's stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.